5PSQ-140 Classification of drug related problems in paediatric patients and acceptance of pharmaceutical interventions

<h3>Background and Importance</h3> Paediatric patients are particularly susceptible to experience drug related problems (DRPs) due to factors such as pharmacokinetic differences or the need to adapt adult dosages/formulations for children. <h3>Aim and Objectives</h3> The present study aims to classify the DRPs identified, analyse the type of pharmaceutical intervention (PI) performed and evaluate the acceptance carried out by the pharmaceutical validation of treatments after the implementation of an assisted electronic prescribing system (AEP) in the paediatric unit of the hospital. The goal is to improve the pharmaceutical care of paediatric patients. <h3>Material and Methods</h3> 19-months observational and retrospective study (June 2022-December 2023) in which the DRPs detected and PIs performed during pharmaceutical validation process were collected and classified. The DRPs were grouped according to necessity, effectiveness or safety; the PIs were grouped based on the type of intervention: dosage adjustment, treatment continuation, schedule modification, change in route of administration, formulation substitution, duplication, and adverse effects/interactions. Subsequently, the acceptance of the PIs was evaluated. <h3>Results</h3> A total of 1,089 patients were included, generating 6,998 validated treatment lines. Within these lines, 208 DRPs were detected (3%): 108 (52%) related to safety, 60 (29%) to effectiveness, and 40 (19%) to necessity. A total of 195 PIs (2.8%) were performed for these DRPs. <h3>The PIs carried out included: </h3> dosage adjustments; 15 (18%) treatment continuation; 17 (9%) protocol changes; 17 (9%) duplication; 14 (7%) schedule modifications; 13 (7%) changes in the route of administration; 14 (7%) formulation substitutions; and 4 (2%) addressing adverse effects/interactions. The acceptance of the PIs was 53% (103) accepted, 47% (92) not assessed/rejected <h3>Conclusion and Relevance</h3> The implementation of the AEP represents a significant contribution to the prevention of DRPs in paediatric patients. 2. 52% of detected DRPs pertained to safety, particularly related to dosage, consistent with paediatric susceptibility. The discrepancy between the number of DRPs and PIs can be attributed to the fact that a single PI may refer to more than one DRP. Over 50% of PIs were accepted, underscoring the pharmacist’s role in prescribing medications for paediatric patients. <h3>References and/or Acknowledgements</h3> <h3>Conflict of Interest</h3> No conflict of interest